Stay in the know
We’ll send you the latest insights and briefings tailored to your needs
Key recent developments in the United Kingdom and Europe relating to patents and the pharmaceutical sector
In this update we welcome our new IP partner in Germany. We have a number of interesting updates from the UK Court of Appeal, including a decision on Arrow declarations, a competition decision, an appeal relating to the lapse of an SPC and a decision on off-label prescription of medical treatments. We cover the German Constitutional Court decision on the UPC and the UK government’s comments on participation in the UPC. We have updates from France on SPCs and a FRAND related injunction. We also discuss several UK High Court decisions on issues such as the use of a public interest defence to avoid an injunction, issue estoppel in patent cases and an example of the interplay between arbitration and IP claims. Throughout the update we consider the impact of COVID-19 and include updates on how the English, French and Italian patent courts are dealing with the crisis.
We announce the hiring of our new IP partner in Germany, Dr Ina vom Feld.
The Court of Appeal has upheld a High Court decision refusing to strike out a request for Arrow relief. The decision confirms that there is no threshold or level of particularity at which an Arrow declaration ought to be formulated.
Following a successful claim for infringement in relation to a mitral valve clip, the High Court considered whether a public interest defence should result in a final injunction being refused or limited. We consider some of the Court’s guidance on how such a defence can operate.
We provide our thoughts on next steps for the Unified Patent Court (UPC) following the German Federal Constitutional Court’s refusal to ratify the UPC Agreement. We also update on the UK government’s position on the UPC.
The Court of Appeal handed down its judgment in a case where the UK Competition and Markets Authority was seeking to reinstate record fines totalling £89.4m imposed on pharmaceutical companies Pfizer and Flynn Pharma in 2016, for abuse of a dominant position through excessive and unfair pricing of an anti-epilepsy drug.
We report on appeals from preliminary injunction decisions handed down in relation to the SPC for ezetimibe+simvastatin.
The Paris Court of Appeal has confirmed an injunction preventing Lenovo from seeking an anti-suit injunction in the US.
We pull together some of our IP related COVID-19 know-how and link to our COVID hub where further resources can be found.
We provide an update on how the patent courts in England, France and Milan are adapting to deal with the COVID-19 crisis and also provide a brief update on the position at the EPO.
The Court of Appeal refused to reinstate an SPC that had lapsed due to failure to pay sufficient fees.
The High Court has considered whether a party should be estopped from raising certain validity arguments in relation to a divisional patent in light of an earlier decision by the same court revoking the parent patent.
The Court of Appeal considered the legality of a policy relating to the prescription of Avastin for off-label treatment.
In an example of an interaction between intellectual property claims and arbitration, the English High Court granted a conditional stay of the claimants’ IP claim pursuant to s 9 of the Arbitration Act 1996 and its inherent case management jurisdiction.
We consider two important pieces of medicines and medical devices regulation currently pending in the UK and the European Union: in the UK, the Medicines and Medical Devices Bill, and in the EU, the Medical Devices Regulation, as well as the impact of COVID on both.
A recent episode in our IP podcast series provides an overview of plausibility.
In an example of an interaction between intellectual property claims and arbitration, the English High Court granted a conditional stay of the claimants’ IP claim pursuant to s 9 of the Arbitration Act 1996 and its inherent case management jurisdiction.
In an example of an interaction between intellectual property claims and arbitration, the English High Court granted a conditional stay of the claimants’ IP claim pursuant to s 9 of the Arbitration Act 1996 and its inherent case management jurisdiction.
The contents of this publication are for reference purposes only and may not be current as at the date of accessing this publication. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action based on this publication.
© Herbert Smith Freehills 2024
We’ll send you the latest insights and briefings tailored to your needs